GLP-1 listings in FDA’s NDC Directory
Which companies list semaglutide, tirzepatide or liraglutide products in FDA’s NDC Directory?
FDA’s NDC Directory files, read Nov 15, 2026, carry 467 product listings naming semaglutide, tirzepatide, liraglutide, retatrutide or cagrilintide. 75 listings from 19 outsourcing facilities carry the category “OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)”, 214 listings are bulk ingredients, and 101 listings are finished drugs under an NDA, ANDA or BLA. FDA says assignment of an NDC number “does not in any way denote FDA approval of the product.”
FDA’s own words on the NDC Directory page (content current as of Mar 4, 2026):
Inclusion in the NDC Directory does not indicate that FDA has verified the information provided or that the products are FDA-approved. The content of each NDC Directory entry is the responsibility of the labeler submitting the SPL file. Assignment of an NDC number does not in any way denote FDA approval of the product. Any representation that creates an impression of FDA approval because a product has an NDC number is misleading and violates federal law. Inclusion in the NDC Directory or assignment of an NDC number does not mean a product is a drug as defined by federal law.
Answer pages: Which outsourcing facilities list compounded semaglutide or tirzepatide with FDA?, Is a listed NDC number the same as FDA approval? FDA’s own words, Which companies list bulk semaglutide or tirzepatide ingredient with FDA?.
Listings by marketing category and drug
Marketing categories are FDA’s, verbatim. A listing that names two tracked drugs counts under each.
| BULK INGREDIENT | 56 | 46 | 34 | 10 | 1 | 147 |
| NDA | 32 | 54 | 5 | 0 | 0 | 91 |
| OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 38 | 33 | 4 | 0 | 0 | 75 |
| DRUG FOR FURTHER PROCESSING | 27 | 42 | 0 | 0 | 0 | 69 |
| BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | 35 | 26 | 5 | 1 | 0 | 67 |
| ANDA | 0 | 0 | 15 | 0 | 0 | 15 |
| NDA AUTHORIZED GENERIC | 0 | 0 | 2 | 0 | 0 | 2 |
| BLA | 0 | 0 | 1 | 0 | 0 | 1 |
Outsourcing facility compounded listings
75 products in FDA’s compounded drugs file carry the category “OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)”. FDA’s file gives reporting periods, not marketing dates.
| Reporting periods | ||||||||
|---|---|---|---|---|---|---|---|---|
| 54288-846 | BPI Labs LLC | Liraglutide Injection, 18 mg/3 mL (6 mg/mL) | Liraglutide Injection, 18 mg/3 mL (6 mg/mL) | INJECTION | SUBCUTANEOUS | 18 mg/3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 73198-151 | Olympia Pharmacy | Liraglutide 6 mg/mL | Liraglutide 6mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 6 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 81375-606 | PQ Pharmacy LLC | Liraglutide | Liraglutide | INJECTION | SUBCUTANEOUS | 6 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2 |
| 81375-614 | PQ Pharmacy LLC | Liraglutide | Liraglutide | INJECTION | SUBCUTANEOUS | 15 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2 |
| 82396-300 | ANNOVEX PHARMA, INC. | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 82396-302 | ANNOVEX PHARMA, INC. | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 82396-305 | ANNOVEX PHARMA, INC. | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 71170-495 | Apollo Care, LLC | Semaglutide 12.5 mg | Semaglutide 12.5 mg | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 |
| 71170-640 | Apollo Care, LLC | Semaglutide 1mg and Cyanocobalamin 0.5mg | Semaglutide 1mg and Cyanocobalamin 0.5mg | INJECTION, SOLUTION | SUBCUTANEOUS | 1 mg/1 mL; .5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2 |
| 71170-650 | Apollo Care, LLC | Semaglutide 2.5mg and Cyanocobalamin 0.5mg | Semaglutide 2.5mg and Cyanocobalamin 0.5mg | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL; .5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2 |
| 71170-690 | Apollo Care, LLC | Semaglutide 12.5mg and Cyanocobalamin 2.5mg | Semaglutide 12.5mg and Cyanocobalamin 2.5mg | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL; .5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2 |
| 71170-811 | Apollo Care, LLC | Semaglutide 2.25 mg | Semaglutide 2.25 mg | INJECTION, SOLUTION | SUBCUTANEOUS | .9 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 |
| 71170-821 | Apollo Care, LLC | Semaglutide 6.75 mg | Semaglutide 6.75 mg | INJECTION, SOLUTION | SUBCUTANEOUS | 4.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 |
| 54288-826 | BPI Labs LLC | Semaglutide Injection, 1 mg/mL | Semaglutide Injection, 1 mg/mL | INJECTION | SUBCUTANEOUS | 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 54288-827 | BPI Labs LLC | Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL) | Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL) | INJECTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 54288-831 | BPI Labs LLC | Semaglutide Injection, 12.5 mg/2.5 mL (5 mg/mL) | Semaglutide Injection, 12.5 mg/2.5 mL (5 mg/mL) | INJECTION | SUBCUTANEOUS | 12.5 mg/2.5 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 54288-833 | BPI Labs LLC | Semaglutide Injection, 2.5mg/mL (1mL vial) | Semaglutide Injection, 2.5mg/mL (1mL vial) | INJECTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 71791-0200 | Delta Pharma INC | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 69852-417 | Eagle Pharma Outsourcing, LLC | Semaglutide 1 mg/mL | Semaglutide 1 mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 1 mg/1 mg | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 69852-517 | Eagle Pharma Outsourcing, LLC | Semaglutide 2.4 mg/mL | Semaglutide 2.4 mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 2.4 mg/2.4 mg | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 72627-2321 | Empower Pharma | Semaglutide/Cyanocobalamin | Semaglutide/Cyanocobalamin | INJECTION | SUBCUTANEOUS | .5 mg/1 mL; 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 72627-2322 | Empower Pharma | Semaglutide/Cyanocobalamin | Semaglutide/Cyanocobalamin | INJECTION | SUBCUTANEOUS | 5 mg/1 mL; .5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 71266-6100 | Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 71266-6110 | Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 26436-5608 | Hybrid Pharma | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1, 2026-1 |
| 26436-5635 | Hybrid Pharma | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1, 2026-1 |
| 70657-1027 | MedisourceRx | Semaglutide | Semaglutide | SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 73013-9000 | OurPharma LLC | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 73013-9001 | OurPharma LLC | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 73013-9002 | OurPharma LLC | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 81375-600 | PQ Pharmacy LLC | Semaglutide | Semaglutide 2.5mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81375-601 | PQ Pharmacy LLC | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81375-605 | PQ Pharmacy LLC | Semaglutide | Semaglutide 5mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 84582-4104 | Signature Rx | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 4 mg/3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 81483-0045 | Tailstorm Health INC | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | .25 mg/.05 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0046 | Tailstorm Health INC | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | .5 mg/.1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0047 | Tailstorm Health INC | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 1 mg/.2 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0048 | Tailstorm Health INC | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 1.7 mg/.22 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0049 | Tailstorm Health INC | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 2.4 mg/.3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 83556-0201 | Turbare Manufacturing | Semaglutide 1 mg/mL | Semaglutide 1 mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 83556-0205 | Turbare Manufacturing | Semaglutide 5 mg/mL | Semaglutide 5 mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 73702-197 | Wells Pharma of Houston | Semaglutide | Semaglutide injection | INJECTION | INTRAMUSCULAR | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 72682-1205 | AnazaoHealth Corporation | Tirzepatide 5mg/mL 2mL | Tirzepatide 5mg/mL Injection 2mL | INJECTION | SUBCUTANEOUS | 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 72682-1220 | AnazaoHealth Corporation | Tirzepatide 20mg/mL 2mL | Tirzepatide 20mg/mL 2mL | INJECTION | SUBCUTANEOUS | 20 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 82396-350 | ANNOVEX PHARMA, INC. | Tirzepatide | Tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 10 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 82396-351 | ANNOVEX PHARMA, INC. | Tirzepatide | Tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 20 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 71170-610 | Apollo Care, LLC | Tirzepatide 20mg and Pyridoxine 8mg | Tirzepatide 20mg and Pyridoxine 8mg | INJECTION, SOLUTION | SUBCUTANEOUS | 10 mg/1 mL; 4 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2 |
| 71170-630 | Apollo Care, LLC | Tirzepatide 60mg and Pyridoxine 12mg | Tirzepatide 60mg and Pyridoxine 12mg | INJECTION, SOLUTION | SUBCUTANEOUS | 20 mg/1 mL; 4 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2 |
| 85091-001 | Apothecary Pharma LLC | Tirzepatide | Tirzepatide Injection | INJECTION, SOLUTION | SUBCUTANEOUS | 18 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 85091-003 | Apothecary Pharma LLC | Tirzepatide | Tirzepatide Injection | INJECTION, SOLUTION | SUBCUTANEOUS | 9 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 85091-004 | Apothecary Pharma LLC | Tirzepatide and B12 | Tirzepatide Injection | INJECTION, SOLUTION | SUBCUTANEOUS | 17 mg/1 mL; 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 85091-005 | Apothecary Pharma LLC | Tirzepatide and B12 | Tirzepatide Injection | INJECTION, SOLUTION | SUBCUTANEOUS | 8.5 mg/1 mL; 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 85091-006 | Apothecary Pharma LLC | Tirzepatide and Glycine | Tirzepatide Injection | INJECTION, SOLUTION | SUBCUTANEOUS | 17 mg/1 mL; 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 54288-832 | BPI Labs LLC | Tirzepatide Injection, 30 mg/3 mL | Tirzepatide Injection, 30 mg/3 mL | INJECTION | SUBCUTANEOUS | 10 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 54288-835 | BPI Labs LLC | Tirzepatide Injection, 10 mg/mL | Tirzepatide Injection, 10 mg/mL | INJECTION | SUBCUTANEOUS | 10 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 54288-836 | BPI Labs LLC | Tirzepatide Injection, 60 mg/3 mL | Tirzepatide Injection, 60 mg/3 mL | INJECTION | SUBCUTANEOUS | 20 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 54288-840 | BPI Labs LLC | Tirzepatide and Pyridoxine Hydrochloride Injection, 30 mg/3 mL (10 mg/mL) and 30 mg/3 mL (10 mg/mL) | Tirzepatide and Pyridoxine Hydrochloride Injection, 30 mg/3 mL (10 mg/mL) and 30 mg/3 mL (10 mg/mL) | INJECTION | SUBCUTANEOUS | 30 mg/3 mL; 30 mg/3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 |
| 54288-841 | BPI Labs LLC | Tirzepatide and Pyridoxine Hydrochloride Injection, 10 mg/mL and 10 mg/mL | Tirzepatide and Pyridoxine Hydrochloride Injection, 10 mg/mL and 10 mg/mL | INJECTION | SUBCUTANEOUS | 10 mg/1 mL; 10 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 |
| 54288-842 | BPI Labs LLC | Tirzepatide and Pyridoxine Hydrochloride Injection, 60 mg/3 mL (20 mg/mL) and 30 mg/3 mL (10 mg/mL) | Tirzepatide and Pyridoxine Hydrochloride Injection, 60 mg/3 mL (20 mg/mL) and 30 mg/3 mL (10 mg/mL) | INJECTION | SUBCUTANEOUS | 30 mg/3 mL; 60 mg/3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 |
| 54288-848 | BPI Labs LLC | Tirzepatide and Pyridoxine Hydrochloride Injection, 40 mg/4 mL (10 mg/mL) and 40 mg/4 mL (10 mg/mL) | Tirzepatide and Pyridoxine Hydrochloride Injection, 40 mg/4 mL (10 mg/mL) and 40 mg/4 mL (10 mg/mL) | INJECTION | SUBCUTANEOUS | 40 mg/4 mL; 40 mg/4 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 |
| 54288-859 | BPI Labs LLC | Tirzepatide and Pyridoxine Hydrochloride Injection, 20 mg/2 mL (10 mg/mL) and 20 mg/2 mL (10 mg/mL) | Tirzepatide and Pyridoxine Hydrochloride Injection, 20 mg/2 mL (10 mg/mL) and 20 mg/2 mL (10 mg/mL) | INJECTION | SUBCUTANEOUS | 20 mg/2 mL; 20 mg/2 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 54288-860 | BPI Labs LLC | Tirzepatide and Pyridoxine Hydrochloride Injection, 68 mg/4 mL (17 mg/mL) and 40 mg/4 mL (10 mg/mL) | Tirzepatide and Pyridoxine Hydrochloride Injection, 68 mg/4 mL (17 mg/mL) and 40 mg/4 mL (10 mg/mL) | INJECTION | SUBCUTANEOUS | 68 mg/4 mL; 40 mg/4 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 72627-2323 | Empower Pharma | Tirzepatide/Niacinamide | Tirzepatide/Niacinamide | INJECTION | SUBCUTANEOUS | 8 mg/1 mL; 2 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 72627-2324 | Empower Pharma | Tirzepatide/Niacinamide | Tirzepatide/Niacinamide | INJECTION | SUBCUTANEOUS | 2 mg/1 mL; 17 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 |
| 26436-5622 | Hybrid Pharma | TIRZEPATIDE 10MG/ML | TIRZEPATIDE 10MG/ML | INJECTION, SOLUTION | SUBCUTANEOUS | 10 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1, 2025-2, 2026-1 |
| 26436-5636 | Hybrid Pharma | TIRZEPATIDE 20MG/ML | TIRZEPATIDE 20MG/ML | INJECTION, SOLUTION | SUBCUTANEOUS | 20 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1, 2025-2, 2026-1 |
| 85049-420 | PGRrx LLC | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 17 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 |
| 81375-610 | PQ Pharmacy LLC | Tirzepatide | Tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 10 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81375-620 | PQ Pharmacy LLC | Tirzepatide | Tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 20 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0050 | Tailstorm Health INC | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 2.4 mg/.1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0051 | Tailstorm Health INC | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 5 mg/.2 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0052 | Tailstorm Health INC | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 7.5 mg/.3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0053 | Tailstorm Health INC | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 10 mg/.2 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0054 | Tailstorm Health INC | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 12.5 mg/.25 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
| 81483-0055 | Tailstorm Health INC | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 15 mg/.3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 |
Labelers
One row per labeler name, grouped by exact name. A labeler links to its page here when one exists under the same name, or to its own NDC page when it has 2 or more compounded or bulk listings and no other page.
| Marketing categories | Drugs | Page here | ||
|---|---|---|---|---|
| A-S Medication Solutions | 17 | NDA (15); ANDA (1); NDA AUTHORIZED GENERIC (1) | Liraglutide, Semaglutide, Tirzepatide | NDA, ANDA or BLA listings only |
| AnazaoHealth Corporation | 2 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (2) | Tirzepatide | 503B facility: AnazaoHealth Corporation, Las Vegas, NV Pharmacy: AnazaoHealth Corporation, Las Vegas, NV |
| ANNOVEX PHARMA, INC. | 5 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (5) | Semaglutide, Tirzepatide | 503B facility: Annovex Pharma, Inc., Lorton, VA Pharmacy: Annovex Pharma, Inc., Lorton, VA |
| Apicore Pharmaceuticals private Limited; Apicore Pharmaceuticals Private Limited | 2 | BULK INGREDIENT (2) | Semaglutide, Tirzepatide | NDC labeler page |
| Apollo Care, LLC | 8 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (8) | Semaglutide, Tirzepatide | 503B facility: Apollo Care, Columbia, MO Pharmacy: Apollo Care, Columbia, MO Pharmacy: Apollo Care LLC, Columbia, MO Company: Apollo Care, LLC |
| Apothecary Pharma LLC | 5 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (5) | Tirzepatide | 503B facility: Apothecary Pharma, LLC, Cary, NC Pharmacy: Apothecary Pharma, LLC, Cary, NC Company: Apothecary Pharma LLC |
| Arene Life Sciences Private Limited | 1 | BULK INGREDIENT (1) | Semaglutide | One compounded or bulk listing |
| Assia Chemical Industries Ltd. - Teva Tech Site | 1 | BULK INGREDIENT (1) | Tirzepatide | One compounded or bulk listing |
| Aurisco Pharmaceutical Co.,Ltd | 19 | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (17); BULK INGREDIENT (2) | Semaglutide, Tirzepatide | NDC labeler page |
| Aurobindo Pharma Limited | 1 | BULK INGREDIENT (1) | Liraglutide | One compounded or bulk listing |
| Bachem AG | 1 | BULK INGREDIENT (1) | Semaglutide | One compounded or bulk listing |
| Bachem Americas, Inc. | 1 | BULK INGREDIENT (1) | Liraglutide | One compounded or bulk listing |
| Bills Biotech Pvt. Ltd. | 1 | BULK INGREDIENT (1) | Semaglutide | One compounded or bulk listing |
| Biocon Limited; BIOCON LIMITED | 3 | BULK INGREDIENT (3) | Liraglutide, Semaglutide, Tirzepatide | NDC labeler page |
| Biocon Pharma Inc. | 2 | ANDA (2) | Liraglutide | NDA, ANDA or BLA listings only |
| BioVectra Inc. | 1 | BULK INGREDIENT (1) | Tirzepatide | One compounded or bulk listing |
| BPI Labs LLC | 14 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (14) | Liraglutide, Semaglutide, Tirzepatide | 503B facility: BPI Labs LLC, Largo, FL Pharmacy: BPI Labs LLC, Largo, FL |
| BSP Pharmaceuticals SpA | 12 | DRUG FOR FURTHER PROCESSING (12) | Tirzepatide | Further-processing listings only |
| Catalent Indiana, LLC | 2 | DRUG FOR FURTHER PROCESSING (2) | Semaglutide | Further-processing listings only |
| Chatnaa Life Sciences LLC | 2 | BULK INGREDIENT (2) | Semaglutide, Tirzepatide | NDC labeler page |
| Chengdu Brilliant Biopharmaceutical Co., Ltd. | 1 | BULK INGREDIENT (1) | Semaglutide | Company: Chengdu Brilliant Biopharmaceutical Co., Ltd. |
| Chengdu Shengnuo Biopharm Co. Ltd.; Chengdu Shengnuo Biopharm Co., Ltd. | 8 | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (5); BULK INGREDIENT (3) | Liraglutide, Semaglutide, Tirzepatide | NDC labeler page |
| Chinese Peptide Company | 1 | BULK INGREDIENT (1) | Semaglutide | One compounded or bulk listing |
| Chongqing Sintaho Pharmaceutical Co., Ltd. | 2 | BULK INGREDIENT (2) | Semaglutide, Tirzepatide | NDC labeler page |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 1 | BULK INGREDIENT (1) | Semaglutide | One compounded or bulk listing |
| Cipla USA Inc. | 2 | ANDA (2) | Liraglutide | NDA, ANDA or BLA listings only |
| Corden Pharma Colorado, Inc. | 1 | BULK INGREDIENT (1) | Tirzepatide | One compounded or bulk listing |
| DARMERICA, LLC | 3 | BULK INGREDIENT (3) | Liraglutide, Semaglutide, Tirzepatide | Company: Darmerica, LLC |
| Delta Pharma INC | 1 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (1) | Semaglutide | 503B facility: Delta Pharma, Inc., Ripley, MS Pharmacy: Delta Pharma, Inc., Ripley, MS |
| Dr. Reddy's Laboratories Limited; Dr. Reddy’s Laboratories Limited | 2 | BULK INGREDIENT (2) | Liraglutide, Semaglutide | NDC labeler page |
| Eagle Pharma Outsourcing, LLC | 2 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (2) | Semaglutide | NDC labeler page |
| El-Peptido (Shanghai) Biopharmaceutical Co., Ltd | 2 | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (2) | Semaglutide, Tirzepatide | NDC labeler page |
| Eli Lilly and Company | 49 | NDA (48); BULK INGREDIENT (1) | Tirzepatide | Brand originator; listed, not paged |
| Eli Lilly Italia SPA | 12 | DRUG FOR FURTHER PROCESSING (12) | Tirzepatide | Brand originator; listed, not paged |
| Empower Pharma | 4 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (4) | Semaglutide, Tirzepatide | 503B facility: Empower Pharma, Houston, TX Pharmacy: Empower Pharma, Houston, TX |
| ETERNAL WEALTH(CHINA)LIMITED | 2 | BULK INGREDIENT (2) | Liraglutide, Retatrutide | NDC labeler page |
| Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories | 2 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (2) | Semaglutide | 503B facility: Fagron Compounding Services dba Fagron Sterile Services, Wichita, KS Pharmacy: Fagron Compounding Services dba Fagron Sterile Services, Wichita, KS Pharmacy: Fagron Sterile Services (Fagron Compounding Services LLC), Wichita, KS Pharmacy: JCB Laboratories, LLC, Wichita, KS |
| FRESENIUS KABI IPSUM SRL | 1 | BULK INGREDIENT (1) | Liraglutide | One compounded or bulk listing |
| Fujian Genohope Biotech Ltd. | 5 | BULK INGREDIENT (5) | Liraglutide, Semaglutide, Tirzepatide | API supplier: Fujian Genohope Biotech Ltd |
| Guangdong Longfu Medicine Co., Ltd. | 1 | BULK INGREDIENT (1) | Tirzepatide | One compounded or bulk listing |
| Hainan Poly Pharm. Co., Ltd. | 1 | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (1) | Semaglutide | One compounded or bulk listing |
| Hangzhou Hotide Biotech Co.,Ltd | 1 | BULK INGREDIENT (1) | Tirzepatide | One compounded or bulk listing |
| Harbin Jixianglong Biotech Co., Ltd. | 2 | BULK INGREDIENT (2) | Retatrutide, Tirzepatide | Company: Harbin Jixianglong Biotech Co., Ltd. API supplier: Harbin Jixianglong Biotech Co., Ltd. |
| HETERO DRUGS LIMITED | 1 | BULK INGREDIENT (1) | Semaglutide | One compounded or bulk listing |
| Hikma Pharmaceuticals USA Inc. | 1 | ANDA (1) | Liraglutide | Pharmacy: Hikma Pharmaceuticals USA Inc., Cherry Hill, NJ |
| Hubei JXBio Pharmaceutical Co.,Ltd; Hubei JXBio Pharmaceutical Co., Ltd | 4 | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (3); BULK INGREDIENT (1) | Liraglutide, Semaglutide, Tirzepatide | API supplier: Hubei JXBio Pharmaceutical Co., Ltd. |
| Hybio Pharmaceutical Co., Ltd.; Hybio Pharmaceutical Co. Ltd; Hybio Pharmaceutical Co., Ltd | 46 | BULK INGREDIENT (26); BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (20) | Liraglutide, Semaglutide, Tirzepatide | API supplier: Hybio Pharmaceutical Co., Ltd. |
| Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | 24 | BULK INGREDIENT (21); ANDA (3) | Liraglutide, Retatrutide, Semaglutide, Tirzepatide | NDC labeler page |
| Hybrid Pharma | 4 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (4) | Semaglutide, Tirzepatide | 503B facility: Hybrid Pharma, LLC, Deerfield Beach, CA Pharmacy: Hybrid Pharma, LLC, Deerfield Beach, CA Pharmacy: Hybrid Pharma LLC, Deerfield Beach, FL |
| Jilin Qijian Bio-Pharmaceutical Co., Ltd. | 1 | BULK INGREDIENT (1) | Semaglutide | One compounded or bulk listing |
| Lupin Pharmaceuticals, Inc. | 1 | ANDA (1) | Liraglutide | NDA, ANDA or BLA listings only |
| Medisca Inc. | 2 | BULK INGREDIENT (2) | Semaglutide, Tirzepatide | NDC labeler page |
| MedisourceRx | 1 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (1) | Semaglutide | 503B facility: MedisourceRx, Los Alamitos, CA Pharmacy: MedisourceRx, Los Alamitos, CA |
| Meitheal Pharmaceuticals Inc. | 1 | ANDA (1) | Liraglutide | NDA, ANDA or BLA listings only |
| MSN Life Sciences Private Limited | 3 | BULK INGREDIENT (3) | Liraglutide, Semaglutide, Tirzepatide | NDC labeler page |
| Nanjing Xingyin Pharmaceutical Group Co.,Ltd | 1 | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (1) | Liraglutide | One compounded or bulk listing |
| NOMIDA LLC; Nomida LLC | 3 | BULK INGREDIENT (3) | Liraglutide, Semaglutide, Tirzepatide | NDC labeler page |
| NorthStar Rx LLC | 1 | ANDA (1) | Liraglutide | NDA, ANDA or BLA listings only |
| Novo Nordisk | 2 | BLA (1); NDA (1) | Liraglutide | Brand originator; listed, not paged |
| Novo Nordisk A/S | 13 | DRUG FOR FURTHER PROCESSING (10); BULK INGREDIENT (3) | Liraglutide, Semaglutide | Brand originator; listed, not paged |
| Novo Nordisk Pharmaceutical Industries, LP | 26 | NDA (26) | Liraglutide, Semaglutide | Brand originator; listed, not paged |
| Novo Nordisk Production Belgium SA | 10 | DRUG FOR FURTHER PROCESSING (10) | Semaglutide | Brand originator; listed, not paged |
| Olympia Pharmacy | 1 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (1) | Liraglutide | Pharmacy: Olympia Pharmacy (OPS International, Inc.), Orlando, FL |
| Orbicular Pharmaceutical Technologies Private Limited | 2 | ANDA (2) | Liraglutide | NDA, ANDA or BLA listings only |
| OurPharma LLC | 3 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (3) | Semaglutide | 503B facility: OurPharma LLC, Fayetteville, AR Pharmacy: OurPharma LLC, Fayetteville, AR |
| Patheon Manufacturing Services LLC | 5 | DRUG FOR FURTHER PROCESSING (5) | Semaglutide | Further-processing listings only |
| PGRrx LLC | 1 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (1) | Tirzepatide | 503B facility: PGRrx LLC, Exton, PA Pharmacy: PGRrx LLC, Exton, PA |
| Pharma Source Direct, Inc. | 2 | BULK INGREDIENT (2) | Semaglutide, Tirzepatide | NDC labeler page |
| Polypeptide Laboratories Inc | 1 | BULK INGREDIENT (1) | Liraglutide | One compounded or bulk listing |
| PolyPeptide SA | 1 | BULK INGREDIENT (1) | Semaglutide | One compounded or bulk listing |
| PQ Pharmacy LLC | 7 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (7) | Liraglutide, Semaglutide, Tirzepatide | 503B facility: PQ Pharmacy LLC, Brooksville, FL Pharmacy: PQ Pharmacy LLC, Brooksville, FL Company: PQ Pharmacy, LLC |
| REMEDYREPACK INC. | 1 | NDA (1) | Semaglutide | NDA, ANDA or BLA listings only |
| Resilience US, LLC | 18 | DRUG FOR FURTHER PROCESSING (18) | Tirzepatide | Further-processing listings only |
| SCH Global Services Private Limited | 1 | BULK INGREDIENT (1) | Semaglutide | One compounded or bulk listing |
| ScinoPharm Taiwan Ltd. | 1 | BULK INGREDIENT (1) | Liraglutide | One compounded or bulk listing |
| Shanghai Ambiopharm, Inc | 2 | BULK INGREDIENT (2) | Liraglutide, Semaglutide | NDC labeler page |
| Shanghai SynTheAll Pharmaceutical Co., Ltd. | 2 | BULK INGREDIENT (1); BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (1) | Retatrutide, Tirzepatide | NDC labeler page |
| Shenzhen Alvantis Pharma Co., Ltd. | 4 | BULK INGREDIENT (2); BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (2) | Cagrilintide, Retatrutide, Semaglutide, Tirzepatide | NDC labeler page |
| SHILPA PHARMA LIFESCIENCES LIMITED | 2 | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (2) | Liraglutide, Semaglutide | NDC labeler page |
| Sichuan Jisheng Biopharmaceutical Co Ltd | 2 | BULK INGREDIENT (2) | Semaglutide, Tirzepatide | NDC labeler page |
| Signature Rx | 1 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (1) | Semaglutide | 503B facility: Signature Rx, Delray Beach, FL Pharmacy: Signature Rx, Delray Beach, FL |
| Sinopep-Allsino Biopharmaceutical Co., Ltd.; Sinopep-Allsino Biopharmaceutical Co.,Ltd. | 10 | BULK INGREDIENT (6); BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (4) | Liraglutide, Retatrutide, Semaglutide, Tirzepatide | NDC labeler page |
| SUN PHARMACEUTICAL INDUSTRIES, INC. | 1 | BULK INGREDIENT (1) | Liraglutide | One compounded or bulk listing |
| Supriya Lifescience Limited | 1 | BULK INGREDIENT (1) | Semaglutide | One compounded or bulk listing |
| Suzhou Lixin Pharmaceutical Co., Ltd. | 2 | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (2) | Semaglutide, Tirzepatide | NDC labeler page |
| Suzhou Tianma Pharma Group Co., Ltd. | 1 | BULK INGREDIENT (1) | Tirzepatide | One compounded or bulk listing |
| Tailstorm Health INC | 11 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (11) | Semaglutide, Tirzepatide | 503B facility: Tailstorm Health Inc., Chandler, AZ Pharmacy: Tailstorm Health Inc., Chandler, AZ Pharmacy: Tailstorm Health, Inc., Phoenix, AZ Company: Tailstorm Health Inc. dba Medivant Health |
| Teva Pharmaceuticals USA, Inc. | 1 | NDA AUTHORIZED GENERIC (1) | Liraglutide | NDA, ANDA or BLA listings only |
| Teva Pharmaceuticals, Inc. | 1 | ANDA (1) | Liraglutide | NDA, ANDA or BLA listings only |
| Thaeta Scientific LLC | 2 | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (2) | Semaglutide, Tirzepatide | NDC labeler page |
| Tonghua Dongbao Pharmaceutical Co., Ltd | 1 | BULK INGREDIENT (1) | Liraglutide | One compounded or bulk listing |
| Turbare Manufacturing | 2 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (2) | Semaglutide | 503B facility: Turbare Manufacturing, Conway, AR Pharmacy: Turbare Manufacturing, Conway, AR |
| Virtu Pharmako (Zhejiang) Co., Ltd. | 6 | BULK INGREDIENT (6) | Semaglutide | NDC labeler page |
| Wells Pharma of Houston | 1 | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (1) | Semaglutide | 503B facility: Wells Pharma of Houston, LLC, Houston, TX Pharmacy: Wells Pharma of Houston, LLC, Houston, TX |
| Zhejiang Jiuzhou Pharmaceutical Co., Ltd. | 1 | BULK INGREDIENT (1) | Semaglutide | One compounded or bulk listing |
| Zhejiang Kingland Pharmaceutical Company Limited | 10 | BULK INGREDIENT (10) | Semaglutide, Tirzepatide | NDC labeler page |
| Zhejiang Peptites Biotech Co., Ltd.; Zhejiang Peptites Biotech Co., Ltd | 3 | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (3) | Liraglutide, Semaglutide, Tirzepatide | API supplier: Zhejiang Peptites Biotech Co.,Ltd. |
| Zhejiang Tasln Biopharma Co., Ltd. | 4 | BULK INGREDIENT (2); BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (2) | Semaglutide, Tirzepatide | NDC labeler page |
| Zhuhai Readline Biotech Co., Ltd. | 1 | BULK INGREDIENT (1) | Semaglutide | One compounded or bulk listing |
Bulk ingredient listings
214 listings in FDA’s unfinished drugs file under “BULK INGREDIENT” or “BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING”. A bulk ingredient listing is a labeler’s report of an active ingredient it makes or handles; it is not a finished drug.
| 84347-007 | Shenzhen Alvantis Pharma Co., Ltd. | Not given | Cagrilintide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Feb 17, 2025 | None given | Dec 31, 2027 |
| 59651-772 | Aurobindo Pharma Limited | Not given | Liraglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Dec 28, 2023 | None given | Dec 31, 2026 |
| 52416-735 | Bachem Americas, Inc. | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Aug 27, 2025 | None given | Dec 31, 2026 |
| 65727-087 | Biocon Limited | Not given | Liraglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Aug 26, 2021 | None given | Dec 31, 2026 |
| 32861-0003 | Chengdu Shengnuo Biopharm Co. Ltd. | Not given | Liraglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Jan 20, 2014 | None given | Dec 31, 2027 |
| 71052-126 | DARMERICA, LLC | Not given | Liraglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | May 10, 2023 | None given | Dec 31, 2026 |
| 71796-022 | Dr. Reddy's Laboratories Limited | Not given | Liraglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Jun 30, 2020 | None given | Dec 31, 2026 |
| 85793-002 | ETERNAL WEALTH(CHINA)LIMITED | Not given | Liraglutide | POWDER | Not given | 100 g/100g | BULK INGREDIENT | Jun 11, 2025 | None given | Dec 31, 2026 |
| 66558-0193 | FRESENIUS KABI IPSUM SRL | Not given | LIRAGLUTIDE | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jun 1, 2021 | None given | Dec 31, 2027 |
| 84502-104 | Fujian Genohope Biotech Ltd. | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Oct 17, 2024 | None given | Dec 31, 2027 |
| 76617-002 | Hubei JXBio Pharmaceutical Co., Ltd | Not given | liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Mar 14, 2024 | None given | Dec 31, 2026 |
| 14403-0021 | Hybio Pharmaceutical Co., Ltd. | Not given | Liraglutide | POWDER | Not given | 1 mg/mg | BULK INGREDIENT | Jun 16, 2025 | None given | Dec 31, 2026 |
| 14403-0021 | Hybio Pharmaceutical Co., Ltd. | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 12, 2025 | None given | Dec 31, 2026 |
| 14403-0021 | Hybio Pharmaceutical Co., Ltd. | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 12, 2025 | None given | Dec 31, 2026 |
| 14403-0021 | Hybio Pharmaceutical Co., Ltd. | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 12, 2025 | None given | Dec 31, 2026 |
| 14403-0009 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 1, 2021 | None given | Dec 31, 2026 |
| 14403-0009 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 1, 2021 | None given | Dec 31, 2026 |
| 14403-0009 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Nov 20, 2024 | None given | Dec 31, 2026 |
| 14403-0009 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 18, 2024 | None given | Dec 31, 2026 |
| 14403-0009 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 18, 2024 | None given | Dec 31, 2026 |
| 14403-0009 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 18, 2024 | None given | Dec 31, 2026 |
| 14403-0009 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 18, 2024 | None given | Dec 31, 2026 |
| 14403-0009 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 18, 2024 | None given | Dec 31, 2026 |
| 14403-0021 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 19, 2024 | None given | Dec 31, 2026 |
| 14403-0021 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 19, 2024 | None given | Dec 31, 2026 |
| 14403-0021 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Mar 13, 2025 | None given | Dec 31, 2026 |
| 69766-034 | MSN Life Sciences Private Limited | Not given | Liraglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Jul 12, 2018 | None given | Dec 31, 2026 |
| 70155-003 | Nanjing Xingyin Pharmaceutical Group Co.,Ltd | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Sep 12, 2017 | None given | Dec 31, 2026 |
| 84223-003 | NOMIDA LLC | Not given | Liraglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Feb 1, 2025 | May 15, 2027 | Not given |
| 0420-9006 | Novo Nordisk A/S | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Feb 1, 2011 | None given | Dec 31, 2026 |
| 63557-2070 | Polypeptide Laboratories Inc | Not given | LIRAGLUTIDE | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 1, 2010 | None given | Dec 31, 2026 |
| 65129-1375 | ScinoPharm Taiwan Ltd. | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Sep 30, 2020 | None given | Dec 31, 2026 |
| 41524-0011 | Shanghai Ambiopharm, Inc | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 12, 2017 | None given | Dec 31, 2027 |
| 82920-504 | SHILPA PHARMA LIFESCIENCES LIMITED | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Apr 30, 2026 | None given | Dec 31, 2027 |
| 76177-018 | Sinopep-Allsino Biopharmaceutical Co., Ltd. | Not given | LIRAGLUTIDE | POWDER | Not given | 1 g/g | BULK INGREDIENT | Feb 1, 2019 | None given | Dec 31, 2027 |
| 76177-118 | Sinopep-Allsino Biopharmaceutical Co., Ltd. | Not given | Liraglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Mar 1, 2019 | None given | Dec 31, 2026 |
| 76177-520 | Sinopep-Allsino Biopharmaceutical Co., Ltd. | Not given | Liraglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Mar 1, 2019 | None given | Dec 31, 2026 |
| 62756-927 | SUN PHARMACEUTICAL INDUSTRIES, INC. | Not given | Liraglutide | POWDER | Not given | 25 kg/25kg | BULK INGREDIENT | Dec 10, 2025 | None given | Dec 31, 2027 |
| 84934-001 | Tonghua Dongbao Pharmaceutical Co., Ltd | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 3, 2024 | None given | Dec 31, 2026 |
| 73569-051 | Zhejiang Peptites Biotech Co., Ltd. | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Dec 6, 2024 | None given | Dec 31, 2027 |
| 85793-001 | ETERNAL WEALTH(CHINA)LIMITED | Not given | Retatrutide | POWDER | Not given | 100 g/100g | BULK INGREDIENT | Jun 11, 2025 | None given | Dec 31, 2026 |
| 84385-103 | Harbin Jixianglong Biotech Co., Ltd. | Not given | Retatrutide | POWDER | Not given | 100 g/100g | BULK INGREDIENT | Jan 9, 2025 | None given | Dec 31, 2026 |
| 14403-0022 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Retatrutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Feb 26, 2025 | None given | Dec 31, 2026 |
| 14403-0022 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Retatrutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Feb 26, 2025 | None given | Dec 31, 2026 |
| 14403-0022 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Retatrutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Feb 26, 2025 | None given | Dec 31, 2026 |
| 14403-0022 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Retatrutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Feb 26, 2025 | None given | Dec 31, 2026 |
| 14403-0022 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Retatrutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Feb 26, 2025 | None given | Dec 31, 2026 |
| 14403-0022 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Retatrutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Feb 26, 2025 | None given | Dec 31, 2026 |
| 24538-803 | Shanghai SynTheAll Pharmaceutical Co., Ltd. | Not given | Retatrutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Apr 16, 2026 | None given | Dec 31, 2027 |
| 84347-003 | Shenzhen Alvantis Pharma Co., Ltd. | Not given | RETATRUTIDE | POWDER | Not given | 1 g/g | BULK INGREDIENT | Feb 17, 2025 | None given | Dec 31, 2027 |
| 76177-055 | Sinopep-Allsino Biopharmaceutical Co.,Ltd. | Not given | Retatrutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Sep 1, 2026 | None given | Dec 31, 2027 |
| 42973-397 | Apicore Pharmaceuticals private Limited | Not given | Semaglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Jun 11, 2024 | None given | Dec 31, 2027 |
| 71859-010 | Arene Life Sciences Private Limited | Not given | semaglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Sep 23, 2026 | None given | Dec 31, 2027 |
| 16812-103 | Aurisco Pharmaceutical Co.,Ltd | Not given | Semaglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Jun 30, 2023 | None given | Dec 31, 2027 |
| 16812-103 | Aurisco Pharmaceutical Co.,Ltd | Not given | Semaglutide | POWDER | Not given | 5 g/5g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Jun 30, 2023 | None given | Dec 31, 2027 |
| 16812-103 | Aurisco Pharmaceutical Co.,Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Jun 30, 2023 | None given | Dec 31, 2027 |
| 16812-103 | Aurisco Pharmaceutical Co.,Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Jun 30, 2023 | None given | Dec 31, 2027 |
| 16812-103 | Aurisco Pharmaceutical Co.,Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Mar 15, 2025 | None given | Dec 31, 2027 |
| 16812-103 | Aurisco Pharmaceutical Co.,Ltd | Not given | Semaglutide | POWDER | Not given | 10 g/10g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Mar 15, 2025 | None given | Dec 31, 2027 |
| 16812-103 | Aurisco Pharmaceutical Co.,Ltd | Not given | Semaglutide | POWDER | Not given | 50 g/50g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Mar 15, 2025 | None given | Dec 31, 2027 |
| 16812-103 | Aurisco Pharmaceutical Co.,Ltd | Not given | Semaglutide | POWDER | Not given | 20 g/20g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Mar 15, 2025 | None given | Dec 31, 2027 |
| 16812-103 | Aurisco Pharmaceutical Co.,Ltd | Not given | Semaglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Jun 30, 2023 | None given | Dec 31, 2027 |
| 55463-0040 | Bachem AG | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Apr 30, 2024 | None given | Dec 31, 2026 |
| 85941-001 | Bills Biotech Pvt. Ltd. | Not given | Semaglutide IH | POWDER | Not given | 100 g/100g | BULK INGREDIENT | Jul 21, 2025 | None given | Dec 31, 2027 |
| 65727-094 | Biocon Limited | Not given | Semaglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Sep 17, 2024 | None given | Dec 31, 2026 |
| 87181-002 | Chatnaa Life Sciences LLC | Not given | Semaglutide | POWDER | Not given | 1 mg/mg | BULK INGREDIENT | Dec 10, 2025 | None given | Dec 31, 2026 |
| 84524-451 | Chengdu Brilliant Biopharmaceutical Co., Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Aug 23, 2024 | None given | Dec 31, 2026 |
| 32861-0011 | Chengdu Shengnuo Biopharm Co. Ltd. | Not given | Semaglutide | POWDER | Not given | 1000 g/1000g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Apr 25, 2024 | None given | Dec 31, 2027 |
| 32861-0011 | Chengdu Shengnuo Biopharm Co. Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Dec 1, 2024 | None given | Dec 31, 2027 |
| 32861-0011 | Chengdu Shengnuo Biopharm Co. Ltd. | Not given | Semaglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Jan 18, 2023 | None given | Dec 31, 2027 |
| 32861-0011 | Chengdu Shengnuo Biopharm Co. Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Dec 1, 2024 | None given | Dec 31, 2027 |
| 32861-0014 | Chengdu Shengnuo Biopharm Co. Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Feb 1, 2026 | None given | Dec 31, 2027 |
| 43963-002 | Chinese Peptide Company | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jul 18, 2023 | None given | Dec 31, 2027 |
| 84172-121 | Chongqing Sintaho Pharmaceutical Co., Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jul 15, 2025 | None given | Dec 31, 2027 |
| 52076-6282 | Chunghwa Chemical Synthesis & Biotech Co., Ltd. | Not given | Semaglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Aug 19, 2024 | None given | Dec 31, 2026 |
| 71052-695 | DARMERICA, LLC | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Apr 25, 2023 | None given | Dec 31, 2027 |
| 71796-039 | Dr. Reddy’s Laboratories Limited | Not given | Semaglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Dec 13, 2021 | None given | Dec 31, 2026 |
| 87370-005 | El-Peptido (Shanghai) Biopharmaceutical Co., Ltd | Not given | SEMAGLUTIDE | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Jan 12, 2026 | None given | Dec 31, 2027 |
| 84502-101 | Fujian Genohope Biotech Ltd. | Not given | semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jul 2, 2024 | None given | Dec 31, 2027 |
| 84502-109 | Fujian Genohope Biotech Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Oct 17, 2025 | None given | Dec 31, 2027 |
| 84502-113 | Fujian Genohope Biotech Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | May 19, 2026 | None given | Dec 31, 2027 |
| 14335-790 | Hainan Poly Pharm. Co., Ltd. | Not given | Semaglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Feb 28, 2025 | None given | Dec 31, 2027 |
| 65977-0165 | HETERO DRUGS LIMITED | Not given | Semaglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Dec 5, 2017 | None given | Dec 31, 2027 |
| 76617-001 | Hubei JXBio Pharmaceutical Co.,Ltd | Not given | semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Nov 17, 2022 | None given | Dec 31, 2026 |
| 76617-003 | Hubei JXBio Pharmaceutical Co.,Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 9, 2025 | None given | Dec 31, 2027 |
| 14403-0018 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Apr 6, 2024 | None given | Dec 31, 2026 |
| 14403-0018 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Oct 13, 2025 | None given | Dec 31, 2026 |
| 14403-0018 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 12, 2025 | None given | Dec 31, 2026 |
| 14403-0018 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Apr 28, 2024 | None given | Dec 31, 2027 |
| 14403-0018 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Apr 28, 2024 | None given | Dec 31, 2027 |
| 14403-0018 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Dec 12, 2025 | None given | Dec 31, 2027 |
| 14403-0018 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Apr 28, 2024 | None given | Dec 31, 2027 |
| 14403-0024 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Sep 4, 2025 | None given | Dec 31, 2026 |
| 14403-0024 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 12, 2025 | None given | Dec 31, 2026 |
| 14403-0024 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Feb 5, 2026 | None given | Dec 31, 2027 |
| 14403-0024 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | May 6, 2026 | None given | Dec 31, 2027 |
| 14403-0024 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | May 6, 2026 | None given | Dec 31, 2027 |
| 14403-0024 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | May 6, 2026 | None given | Dec 31, 2027 |
| 14403-0024 | Hybio Pharmaceutical Co. Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | May 7, 2026 | None given | Dec 31, 2027 |
| 14403-0018 | Hybio Pharmaceutical Co., Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Apr 28, 2024 | None given | Dec 31, 2026 |
| 14403-0024 | Hybio Pharmaceutical Co., Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Sep 17, 2026 | None given | Dec 31, 2027 |
| 14403-0024 | Hybio Pharmaceutical Co., Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Sep 18, 2026 | None given | Dec 31, 2027 |
| 14403-0030 | Hybio Pharmaceutical Co., Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Sep 22, 2026 | None given | Dec 31, 2027 |
| 14403-0030 | Hybio Pharmaceutical Co., Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Sep 22, 2026 | None given | Dec 31, 2027 |
| 14403-0024 | Hybio Pharmaceutical Co., Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 12, 2025 | None given | Dec 31, 2026 |
| 14403-0030 | Hybio Pharmaceutical Co., Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Oct 16, 2026 | None given | Dec 31, 2027 |
| 14403-0018 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jun 28, 2024 | None given | Dec 31, 2026 |
| 85717-003 | Jilin Qijian Bio-Pharmaceutical Co., Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Sep 14, 2026 | None given | Dec 31, 2027 |
| 38779-3373 | Medisca Inc. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Apr 10, 2026 | None given | Dec 31, 2027 |
| 69766-108 | MSN Life Sciences Private Limited | Not given | Semaglutide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Sep 23, 2023 | None given | Dec 31, 2026 |
| 84223-001 | NOMIDA LLC | Not given | Semaglutide | POWDER | Not given | 1 mg/mg | BULK INGREDIENT | Apr 15, 2024 | May 15, 2027 | Not given |
| 0420-9008 | Novo Nordisk A/S | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 6, 2017 | None given | Dec 31, 2027 |
| 0420-9511 | Novo Nordisk A/S | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Nov 10, 2021 | None given | Dec 31, 2027 |
| 82393-406 | Pharma Source Direct, Inc. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jul 1, 2024 | None given | Dec 31, 2026 |
| 68067-2602 | PolyPeptide SA | Not given | SEMAGLUTIDE | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jun 1, 2020 | None given | Dec 31, 2027 |
| 85207-019 | SCH Global Services Private Limited | Not given | Semaglutide | POWDER | Not given | 100 g/100g | BULK INGREDIENT | Aug 1, 2025 | None given | Dec 31, 2026 |
| 41524-0012 | Shanghai Ambiopharm, Inc | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 11, 2021 | None given | Dec 31, 2027 |
| 84347-001 | Shenzhen Alvantis Pharma Co., Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | May 23, 2024 | None given | Dec 31, 2027 |
| 82920-505 | SHILPA PHARMA LIFESCIENCES LIMITED | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Apr 30, 2026 | None given | Dec 31, 2027 |
| 85165-010 | Sichuan Jisheng Biopharmaceutical Co Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 21, 2025 | None given | Dec 31, 2026 |
| 76177-022 | Sinopep-Allsino Biopharmaceutical Co., Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Nov 1, 2023 | None given | Dec 31, 2026 |
| 76177-054 | Sinopep-Allsino Biopharmaceutical Co., Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Mar 1, 2021 | None given | Dec 31, 2026 |
| 76177-521 | Sinopep-Allsino Biopharmaceutical Co., Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Mar 1, 2021 | None given | Dec 31, 2027 |
| 61281-8700 | Supriya Lifescience Limited | Not given | SEMAGLUTIDE | POWDER | Not given | 1 g/g | BULK INGREDIENT | Sep 25, 2024 | None given | Dec 31, 2026 |
| 29930-009 | Suzhou Lixin Pharmaceutical Co., Ltd. | Not given | semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Nov 20, 2024 | None given | Dec 31, 2026 |
| 87155-106 | Thaeta Scientific LLC | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Oct 15, 2025 | None given | Dec 31, 2027 |
| 85827-301 | Virtu Pharmako (Zhejiang) Co., Ltd. | Not given | semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 1, 2026 | None given | Dec 31, 2026 |
| 85827-301 | Virtu Pharmako (Zhejiang) Co., Ltd. | Not given | semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 24, 2025 | None given | Dec 31, 2026 |
| 85827-301 | Virtu Pharmako (Zhejiang) Co., Ltd. | Not given | semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 31, 2025 | None given | Dec 31, 2026 |
| 85827-302 | Virtu Pharmako (Zhejiang) Co., Ltd. | Not given | semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 1, 2026 | None given | Dec 31, 2026 |
| 85827-302 | Virtu Pharmako (Zhejiang) Co., Ltd. | Not given | semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 20, 2025 | None given | Dec 31, 2026 |
| 85827-302 | Virtu Pharmako (Zhejiang) Co., Ltd. | Not given | semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Dec 31, 2025 | None given | Dec 31, 2026 |
| 65344-0041 | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Feb 13, 2026 | None given | Dec 31, 2027 |
| 84824-005 | Zhejiang Kingland Pharmaceutical Company Limited | Not given | semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 20, 2025 | None given | Dec 31, 2026 |
| 84824-005 | Zhejiang Kingland Pharmaceutical Company Limited | Not given | semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 21, 2025 | None given | Dec 31, 2026 |
| 84824-005 | Zhejiang Kingland Pharmaceutical Company Limited | Not given | semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 21, 2025 | None given | Dec 31, 2026 |
| 84824-005 | Zhejiang Kingland Pharmaceutical Company Limited | Not given | semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 21, 2025 | None given | Dec 31, 2026 |
| 84824-005 | Zhejiang Kingland Pharmaceutical Company Limited | Not given | semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 21, 2025 | None given | Dec 31, 2026 |
| 73569-035 | Zhejiang Peptites Biotech Co., Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Oct 26, 2022 | None given | Dec 31, 2027 |
| 84643-101 | Zhejiang Tasln Biopharma Co., Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Nov 5, 2025 | None given | Dec 31, 2026 |
| 84643-101 | Zhejiang Tasln Biopharma Co., Ltd. | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Feb 12, 2026 | None given | Dec 31, 2027 |
| 87730-004 | Zhuhai Readline Biotech Co., Ltd. | Not given | Semaglutide | POWDER | Not given | 100 g/100g | BULK INGREDIENT | May 27, 2026 | None given | Dec 31, 2027 |
| 42973-383 | Apicore Pharmaceuticals Private Limited | Not given | Tirzepatide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Jun 11, 2024 | None given | Dec 31, 2026 |
| 63415-0533 | Assia Chemical Industries Ltd. - Teva Tech Site | Not given | Tirzepatide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | May 20, 2025 | None given | Dec 31, 2026 |
| 16812-104 | Aurisco Pharmaceutical Co.,Ltd | Not given | Tirzepatide | POWDER | Not given | 50 g/50g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Oct 16, 2024 | None given | Dec 31, 2027 |
| 16812-104 | Aurisco Pharmaceutical Co.,Ltd | Not given | Tirzepatide | POWDER | Not given | 10 g/10g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Oct 16, 2024 | None given | Dec 31, 2027 |
| 16812-104 | Aurisco Pharmaceutical Co.,Ltd | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Oct 16, 2024 | None given | Dec 31, 2027 |
| 16812-104 | Aurisco Pharmaceutical Co.,Ltd | Not given | Tirzepatide | POWDER | Not given | 25 mg/25mg | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Oct 16, 2024 | None given | Dec 31, 2027 |
| 16812-104 | Aurisco Pharmaceutical Co.,Ltd | Not given | Tirzepatide | POWDER | Not given | 100 g/100g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Oct 16, 2024 | None given | Dec 31, 2027 |
| 16812-104 | Aurisco Pharmaceutical Co.,Ltd | Not given | Tirzepatide | POWDER | Not given | 5 g/5g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Oct 16, 2024 | None given | Dec 31, 2027 |
| 16812-104 | Aurisco Pharmaceutical Co.,Ltd | Not given | Tirzepatide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Oct 16, 2024 | None given | Dec 31, 2027 |
| 16812-104 | Aurisco Pharmaceutical Co.,Ltd | Not given | Tirzepatide | POWDER | Not given | 20 g/20g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Oct 16, 2024 | None given | Dec 31, 2027 |
| 16812-104 | Aurisco Pharmaceutical Co.,Ltd | Not given | Tirzepatide | POWDER | Not given | 500 g/500g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Jul 1, 2026 | None given | Dec 31, 2027 |
| 16812-104 | Aurisco Pharmaceutical Co.,Ltd | Not given | Tirzepatide | POWDER | Not given | 200 g/200g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Oct 16, 2024 | None given | Dec 31, 2027 |
| 65727-109 | BIOCON LIMITED | Not given | TIRZEPATIDE | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Oct 22, 2025 | None given | Dec 31, 2026 |
| 63474-700 | BioVectra Inc. | Not given | Tirzepatide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Jan 27, 2025 | None given | Dec 31, 2026 |
| 87181-003 | Chatnaa Life Sciences LLC | Not given | Tirzepatide | POWDER | Not given | 1 mg/mg | BULK INGREDIENT | Dec 30, 2025 | None given | Dec 31, 2026 |
| 32861-0013 | Chengdu Shengnuo Biopharm Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 100 g/100g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Nov 10, 2025 | None given | Dec 31, 2027 |
| 32861-0013 | Chengdu Shengnuo Biopharm Co., Ltd. | Not given | tirzepatide | POWDER | Not given | 100 g/100g | BULK INGREDIENT | Apr 1, 2026 | None given | Dec 31, 2027 |
| 84172-201 | Chongqing Sintaho Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Sep 1, 2026 | None given | Dec 31, 2027 |
| 12869-210 | Corden Pharma Colorado, Inc. | Not given | Tirzepatide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | May 16, 2022 | None given | Dec 31, 2026 |
| 71052-167 | DARMERICA, LLC | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | May 2, 2023 | None given | Dec 31, 2027 |
| 87370-008 | El-Peptido (Shanghai) Biopharmaceutical Co., Ltd | Not given | TIRZEPATIDE | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Jan 12, 2026 | None given | Dec 31, 2027 |
| 0002-0770 | Eli Lilly and Company | Not given | tirzepatide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Jun 20, 2023 | None given | Dec 31, 2026 |
| 84502-103 | Fujian Genohope Biotech Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jul 31, 2024 | None given | Dec 31, 2027 |
| 85781-001 | Guangdong Longfu Medicine Co., Ltd. | Not given | TIRZEPATIDE | POWDER | Not given | 10 g/10g | BULK INGREDIENT | Jun 9, 2025 | None given | Dec 31, 2026 |
| 83783-001 | Hangzhou Hotide Biotech Co.,Ltd | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 1, 2025 | None given | Dec 31, 2026 |
| 84385-104 | Harbin Jixianglong Biotech Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 100 g/100g | BULK INGREDIENT | May 9, 2025 | None given | Dec 31, 2027 |
| 76617-020 | Hubei JXBio Pharmaceutical Co.,Ltd | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Dec 5, 2022 | None given | Dec 31, 2026 |
| 14403-0017 | Hybio Pharmaceutical Co. Ltd | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Mar 28, 2024 | None given | Dec 31, 2026 |
| 14403-0029 | Hybio Pharmaceutical Co. Ltd | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Sep 16, 2026 | None given | Dec 31, 2027 |
| 14403-0017 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Apr 26, 2024 | None given | Dec 31, 2026 |
| 14403-0017 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Apr 26, 2024 | None given | Dec 31, 2026 |
| 14403-0017 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Apr 26, 2024 | None given | Dec 31, 2026 |
| 14403-0017 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Jun 26, 2024 | None given | Dec 31, 2027 |
| 14403-0017 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Jun 26, 2024 | None given | Dec 31, 2027 |
| 14403-0017 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Jun 26, 2024 | None given | Dec 31, 2027 |
| 14403-0017 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Jun 26, 2024 | None given | Dec 31, 2027 |
| 14403-0017 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Jun 26, 2024 | None given | Dec 31, 2027 |
| 14403-0020 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Jun 26, 2024 | None given | Dec 31, 2026 |
| 14403-0020 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Apr 1, 2024 | None given | Dec 31, 2026 |
| 14403-0020 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jun 26, 2024 | None given | Dec 31, 2026 |
| 14403-0020 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jun 26, 2024 | None given | Dec 31, 2026 |
| 14403-0020 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jun 26, 2024 | None given | Dec 31, 2026 |
| 14403-0020 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jun 26, 2024 | None given | Dec 31, 2026 |
| 14403-0020 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jun 26, 2024 | None given | Dec 31, 2026 |
| 14403-0020 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jun 26, 2024 | None given | Dec 31, 2026 |
| 14403-0027 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Oct 13, 2026 | None given | Dec 31, 2027 |
| 14403-0028 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 23, 2026 | None given | Dec 31, 2027 |
| 14403-0028 | Hybio Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 23, 2026 | None given | Dec 31, 2027 |
| 14403-0017 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jun 26, 2024 | None given | Dec 31, 2026 |
| 14403-0020 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Tirzepatide | POWDER | Not given | 1 mg/mg | BULK INGREDIENT | Jun 26, 2024 | None given | Dec 31, 2026 |
| 14403-0020 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jun 26, 2024 | None given | Dec 31, 2026 |
| 38779-3372 | Medisca Inc. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Apr 10, 2026 | None given | Dec 31, 2027 |
| 69766-122 | MSN Life Sciences Private Limited | Not given | Tirzepatide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT | Feb 7, 2026 | None given | Dec 31, 2027 |
| 84223-002 | Nomida LLC | Not given | Tirzepatide | POWDER | Not given | 1 mg/mg | BULK INGREDIENT | Apr 15, 2024 | May 15, 2027 | Not given |
| 82393-407 | Pharma Source Direct, Inc. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jul 1, 2024 | None given | Dec 31, 2026 |
| 24538-599 | Shanghai SynTheAll Pharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 kg/kg | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Apr 1, 2025 | None given | Dec 31, 2027 |
| 84347-002 | Shenzhen Alvantis Pharma Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | May 23, 2024 | None given | Dec 31, 2026 |
| 85165-012 | Sichuan Jisheng Biopharmaceutical Co Ltd | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 21, 2025 | None given | Dec 31, 2026 |
| 76177-192 | Sinopep-Allsino Biopharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 10, 2023 | None given | Dec 31, 2026 |
| 76177-192 | Sinopep-Allsino Biopharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Jan 10, 2023 | None given | Dec 31, 2027 |
| 76177-501 | Sinopep-Allsino Biopharmaceutical Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Nov 1, 2023 | None given | Dec 31, 2026 |
| 29930-010 | Suzhou Lixin Pharmaceutical Co., Ltd. | Not given | tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Nov 20, 2024 | None given | Dec 31, 2026 |
| 67649-0014 | Suzhou Tianma Pharma Group Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Sep 28, 2026 | None given | Dec 31, 2027 |
| 87155-105 | Thaeta Scientific LLC | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Oct 15, 2025 | None given | Dec 31, 2027 |
| 84824-006 | Zhejiang Kingland Pharmaceutical Company Limited | Not given | tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 21, 2025 | None given | Dec 31, 2026 |
| 84824-006 | Zhejiang Kingland Pharmaceutical Company Limited | Not given | tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 21, 2025 | None given | Dec 31, 2026 |
| 84824-006 | Zhejiang Kingland Pharmaceutical Company Limited | Not given | tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 21, 2025 | None given | Dec 31, 2026 |
| 84824-006 | Zhejiang Kingland Pharmaceutical Company Limited | Not given | tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 21, 2025 | None given | Dec 31, 2026 |
| 84824-006 | Zhejiang Kingland Pharmaceutical Company Limited | Not given | tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 21, 2025 | None given | Dec 31, 2027 |
| 73569-050 | Zhejiang Peptites Biotech Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Dec 29, 2023 | None given | Dec 31, 2027 |
| 84643-102 | Zhejiang Tasln Biopharma Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Feb 5, 2026 | None given | Dec 31, 2026 |
| 84643-102 | Zhejiang Tasln Biopharma Co., Ltd. | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Mar 11, 2026 | None given | Dec 31, 2027 |
Drug for further processing
| 61434-067 | Catalent Indiana, LLC | Not given | semaglutide | INJECTION, SOLUTION | Not given | 1.7 mg/.75mL | DRUG FOR FURTHER PROCESSING | Jul 22, 2024 | None given | Dec 31, 2027 |
| 61434-068 | Catalent Indiana, LLC | Not given | semaglutide | INJECTION, SOLUTION | Not given | 2.4 mg/.75mL | DRUG FOR FURTHER PROCESSING | Jul 22, 2024 | None given | Dec 31, 2027 |
| 0420-9237 | Novo Nordisk A/S | Not given | semaglutide | INJECTION, SOLUTION | Not given | .68 mg/mL | DRUG FOR FURTHER PROCESSING | Dec 6, 2017 | None given | Dec 31, 2026 |
| 0420-9300 | Novo Nordisk A/S | Not given | Semaglutide | INJECTION, SOLUTION | Not given | .5 mg/.5mL | DRUG FOR FURTHER PROCESSING | Jun 2, 2017 | None given | Dec 31, 2027 |
| 0420-9301 | Novo Nordisk A/S | Not given | Semaglutide | INJECTION, SOLUTION | Not given | .25 mg/.5mL | DRUG FOR FURTHER PROCESSING | May 7, 2026 | None given | Dec 31, 2027 |
| 0420-9302 | Novo Nordisk A/S | Not given | Semaglutide | INJECTION, SOLUTION | Not given | 1 mg/.5mL | DRUG FOR FURTHER PROCESSING | Apr 28, 2026 | None given | Dec 31, 2027 |
| 0420-9317 | Novo Nordisk A/S | Not given | Semaglutide | INJECTION, SOLUTION | Not given | 1.7 mg/.75mL | DRUG FOR FURTHER PROCESSING | Apr 28, 2026 | None given | Dec 31, 2027 |
| 0420-9324 | Novo Nordisk A/S | Not given | Semaglutide | INJECTION, SOLUTION | Not given | 2.4 mg/.75mL | DRUG FOR FURTHER PROCESSING | Apr 28, 2026 | None given | Dec 31, 2027 |
| 0420-9520 | Novo Nordisk A/S | Not given | Semaglutide SNAC | TABLET | Not given | 3 mg/1 | DRUG FOR FURTHER PROCESSING | Sep 20, 2019 | None given | Dec 31, 2027 |
| 0420-9530 | Novo Nordisk A/S | Not given | Semaglutide SNAC | TABLET | Not given | 7 mg/1 | DRUG FOR FURTHER PROCESSING | Sep 20, 2019 | None given | Dec 31, 2027 |
| 0420-9540 | Novo Nordisk A/S | Not given | Semaglutide SNAC | TABLET | Not given | 14 mg/1 | DRUG FOR FURTHER PROCESSING | Sep 20, 2019 | None given | Dec 31, 2027 |
| 0420-9600 | Novo Nordisk A/S | Not given | semaglutide | INJECTION, SOLUTION | Not given | 2.68 mg/mL | DRUG FOR FURTHER PROCESSING | Apr 29, 2026 | None given | Dec 31, 2027 |
| 43835-0028 | Novo Nordisk Production Belgium SA | Not given | semaglutide | INJECTION, SOLUTION | Not given | .5 mg/mL | DRUG FOR FURTHER PROCESSING | Jun 5, 2021 | None given | Dec 31, 2027 |
| 43835-0029 | Novo Nordisk Production Belgium SA | Not given | semaglutide | INJECTION, SOLUTION | Not given | 1 mg/mL | DRUG FOR FURTHER PROCESSING | Jun 5, 2021 | None given | Dec 31, 2027 |
| 43835-0030 | Novo Nordisk Production Belgium SA | Not given | semaglutide | INJECTION, SOLUTION | Not given | 2 mg/mL | DRUG FOR FURTHER PROCESSING | Jun 5, 2021 | None given | Dec 31, 2027 |
| 43835-0031 | Novo Nordisk Production Belgium SA | Not given | semaglutide | INJECTION, SOLUTION | Not given | 1.7 mg/.75mL | DRUG FOR FURTHER PROCESSING | Jun 5, 2021 | None given | Dec 31, 2027 |
| 43835-0032 | Novo Nordisk Production Belgium SA | Not given | semaglutide | INJECTION, SOLUTION | Not given | 2.4 mg/.75mL | DRUG FOR FURTHER PROCESSING | Apr 14, 2022 | None given | Dec 31, 2027 |
| 43835-0055 | Novo Nordisk Production Belgium SA | Not given | Semaglutide | INJECTION, SOLUTION | Not given | .5 mg/.5mL | DRUG FOR FURTHER PROCESSING | Jan 1, 2025 | None given | Dec 31, 2027 |
| 43835-0056 | Novo Nordisk Production Belgium SA | Not given | Semaglutide | INJECTION, SOLUTION | Not given | 1 mg/.5mL | DRUG FOR FURTHER PROCESSING | Jan 1, 2025 | None given | Dec 31, 2027 |
| 43835-0057 | Novo Nordisk Production Belgium SA | Not given | Semaglutide | INJECTION, SOLUTION | Not given | 2 mg/.5mL | DRUG FOR FURTHER PROCESSING | Jan 1, 2025 | None given | Dec 31, 2027 |
| 43835-0058 | Novo Nordisk Production Belgium SA | Not given | Semaglutide | INJECTION, SOLUTION | Not given | 2.27 mg/.75mL | DRUG FOR FURTHER PROCESSING | Jan 1, 2025 | None given | Dec 31, 2027 |
| 43835-0059 | Novo Nordisk Production Belgium SA | Not given | Semaglutide | INJECTION, SOLUTION | Not given | 3.2 mg/.75mL | DRUG FOR FURTHER PROCESSING | Jan 1, 2025 | None given | Dec 31, 2027 |
| 63552-200 | Patheon Manufacturing Services LLC | Not given | semaglutide | INJECTION, SOLUTION | Not given | .25 mg/.5mL | DRUG FOR FURTHER PROCESSING | Jun 5, 2021 | None given | Dec 31, 2027 |
| 63552-201 | Patheon Manufacturing Services LLC | Not given | semaglutide | INJECTION, SOLUTION | Not given | .5 mg/.5mL | DRUG FOR FURTHER PROCESSING | Jun 5, 2021 | None given | Dec 31, 2027 |
| 63552-203 | Patheon Manufacturing Services LLC | Not given | semaglutide | INJECTION, SOLUTION | Not given | 1.7 mg/.75mL | DRUG FOR FURTHER PROCESSING | Jun 5, 2021 | None given | Dec 31, 2027 |
| 63552-205 | Patheon Manufacturing Services LLC | Not given | semaglutide | INJECTION, SOLUTION | Not given | 1 mg/.5mL | DRUG FOR FURTHER PROCESSING | Jun 5, 2021 | None given | Dec 31, 2027 |
| 63552-206 | Patheon Manufacturing Services LLC | Not given | semaglutide | INJECTION, SOLUTION | Not given | 2.4 mg/.75mL | DRUG FOR FURTHER PROCESSING | Jun 5, 2021 | None given | Dec 31, 2027 |
| 43624-015 | BSP Pharmaceuticals SpA | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 2.5 mg/.5mL | DRUG FOR FURTHER PROCESSING | Aug 1, 2023 | None given | Dec 31, 2026 |
| 43624-016 | BSP Pharmaceuticals SpA | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 5 mg/.5mL | DRUG FOR FURTHER PROCESSING | Aug 1, 2023 | None given | Dec 31, 2026 |
| 43624-017 | BSP Pharmaceuticals SpA | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 7.5 mg/.5mL | DRUG FOR FURTHER PROCESSING | Aug 1, 2023 | None given | Dec 31, 2026 |
| 43624-018 | BSP Pharmaceuticals SpA | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 10 mg/.5mL | DRUG FOR FURTHER PROCESSING | Aug 1, 2023 | None given | Dec 31, 2026 |
| 43624-019 | BSP Pharmaceuticals SpA | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 12.5 mg/.5mL | DRUG FOR FURTHER PROCESSING | Aug 1, 2023 | None given | Dec 31, 2026 |
| 43624-020 | BSP Pharmaceuticals SpA | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 15 mg/.5mL | DRUG FOR FURTHER PROCESSING | Aug 1, 2023 | None given | Dec 31, 2026 |
| 43624-033 | BSP Pharmaceuticals SpA | Not given | Multiple-Dose Tirzepatide Injection | INJECTION, SOLUTION | Not given | 2.5 mg/.6mL | DRUG FOR FURTHER PROCESSING | Nov 30, 2025 | None given | Dec 31, 2026 |
| 43624-034 | BSP Pharmaceuticals SpA | Not given | Multiple-Dose Tirzepatide Injection | INJECTION, SOLUTION | Not given | 5 mg/.6mL | DRUG FOR FURTHER PROCESSING | Nov 30, 2025 | None given | Dec 31, 2026 |
| 43624-035 | BSP Pharmaceuticals SpA | Not given | Multiple-Dose Tirzepatide Injection | INJECTION, SOLUTION | Not given | 7.5 mg/.6mL | DRUG FOR FURTHER PROCESSING | Nov 30, 2025 | None given | Dec 31, 2026 |
| 43624-036 | BSP Pharmaceuticals SpA | Not given | Multiple-Dose Tirzepatide Injection | INJECTION, SOLUTION | Not given | 10 mg/.6mL | DRUG FOR FURTHER PROCESSING | Nov 30, 2025 | None given | Dec 31, 2026 |
| 43624-037 | BSP Pharmaceuticals SpA | Not given | Multiple-Dose Tirzepatide Injection | INJECTION, SOLUTION | Not given | 12.5 mg/.6mL | DRUG FOR FURTHER PROCESSING | Nov 30, 2025 | None given | Dec 31, 2026 |
| 43624-038 | BSP Pharmaceuticals SpA | Not given | Multiple-Dose Tirzepatide Injection | INJECTION, SOLUTION | Not given | 15 mg/.6mL | DRUG FOR FURTHER PROCESSING | Nov 30, 2025 | None given | Dec 31, 2026 |
| 54568-043 | Eli Lilly Italia SPA | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 5 mg/.5mL | DRUG FOR FURTHER PROCESSING | Aug 12, 2022 | None given | Dec 31, 2026 |
| 54568-170 | Eli Lilly Italia SPA | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 2.5 mg/.5mL | DRUG FOR FURTHER PROCESSING | Aug 12, 2022 | None given | Dec 31, 2026 |
| 54568-325 | Eli Lilly Italia SPA | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 15 mg/.5mL | DRUG FOR FURTHER PROCESSING | Jul 13, 2023 | None given | Dec 31, 2026 |
| 54568-341 | Eli Lilly Italia SPA | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 15 mg/.6mL | DRUG FOR FURTHER PROCESSING | Feb 6, 2024 | None given | Dec 31, 2027 |
| 54568-342 | Eli Lilly Italia SPA | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 12.5 mg/.6mL | DRUG FOR FURTHER PROCESSING | Feb 6, 2024 | None given | Dec 31, 2027 |
| 54568-343 | Eli Lilly Italia SPA | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 10 mg/.6mL | DRUG FOR FURTHER PROCESSING | Feb 6, 2024 | None given | Dec 31, 2027 |
| 54568-344 | Eli Lilly Italia SPA | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 7.5 mg/.6mL | DRUG FOR FURTHER PROCESSING | Feb 6, 2024 | None given | Dec 31, 2027 |
| 54568-345 | Eli Lilly Italia SPA | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 5 mg/.6mL | DRUG FOR FURTHER PROCESSING | Feb 6, 2024 | None given | Dec 31, 2027 |
| 54568-346 | Eli Lilly Italia SPA | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 2.5 mg/.6mL | DRUG FOR FURTHER PROCESSING | Feb 6, 2024 | None given | Dec 31, 2027 |
| 54568-460 | Eli Lilly Italia SPA | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 12.5 mg/.5mL | DRUG FOR FURTHER PROCESSING | Aug 12, 2022 | None given | Dec 31, 2026 |
| 54568-471 | Eli Lilly Italia SPA | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 10 mg/.5mL | DRUG FOR FURTHER PROCESSING | Aug 12, 2022 | None given | Dec 31, 2026 |
| 54568-837 | Eli Lilly Italia SPA | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 7.5 mg/.5mL | DRUG FOR FURTHER PROCESSING | Jul 13, 2023 | None given | Dec 31, 2026 |
| 83516-0241 | Resilience US, LLC | Not given | Tirzepatide | INJECTION, SOLUTION | Not given | 2.5 mg/.5mL | DRUG FOR FURTHER PROCESSING | Dec 27, 2024 | None given | Dec 31, 2027 |
| 83516-0242 | Resilience US, LLC | Not given | Tirzepatide | INJECTION, SOLUTION | Not given | 5 mg/.5mL | DRUG FOR FURTHER PROCESSING | Dec 27, 2024 | None given | Dec 31, 2027 |
| 83516-0243 | Resilience US, LLC | Not given | Tirzepatide | INJECTION, SOLUTION | Not given | 7.5 mg/.5mL | DRUG FOR FURTHER PROCESSING | Dec 27, 2024 | None given | Dec 31, 2027 |
| 83516-0244 | Resilience US, LLC | Not given | Tirzepatide | INJECTION, SOLUTION | Not given | 10 mg/.5mL | DRUG FOR FURTHER PROCESSING | Dec 27, 2024 | None given | Dec 31, 2027 |
| 83516-0245 | Resilience US, LLC | Not given | Tirzepatide | INJECTION, SOLUTION | Not given | 12.5 mg/.5mL | DRUG FOR FURTHER PROCESSING | Dec 27, 2024 | None given | Dec 31, 2027 |
| 83516-0246 | Resilience US, LLC | Not given | Tirzepatide | INJECTION, SOLUTION | Not given | 15 mg/.5mL | DRUG FOR FURTHER PROCESSING | Dec 27, 2024 | None given | Dec 31, 2027 |
| 83516-0247 | Resilience US, LLC | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 2.5 mg/.5mL | DRUG FOR FURTHER PROCESSING | May 15, 2024 | None given | Dec 31, 2027 |
| 83516-0248 | Resilience US, LLC | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 5 mg/.5mL | DRUG FOR FURTHER PROCESSING | May 15, 2024 | None given | Dec 31, 2027 |
| 83516-0249 | Resilience US, LLC | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 7.5 mg/.5mL | DRUG FOR FURTHER PROCESSING | May 15, 2024 | None given | Dec 31, 2027 |
| 83516-0250 | Resilience US, LLC | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 10 mg/.5mL | DRUG FOR FURTHER PROCESSING | May 15, 2024 | None given | Dec 31, 2027 |
| 83516-0251 | Resilience US, LLC | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 12.5 mg/.5mL | DRUG FOR FURTHER PROCESSING | May 15, 2024 | None given | Dec 31, 2027 |
| 83516-0252 | Resilience US, LLC | Not given | tirzepatide | INJECTION, SOLUTION | Not given | 15 mg/.5mL | DRUG FOR FURTHER PROCESSING | May 15, 2024 | None given | Dec 31, 2027 |
| 83516-0257 | Resilience US, LLC | Not given | Tirzepatide | INJECTION, SOLUTION | Not given | 2.5 mg/.5mL | DRUG FOR FURTHER PROCESSING | May 6, 2025 | None given | Dec 31, 2027 |
| 83516-0258 | Resilience US, LLC | Not given | Tirzepatide | INJECTION, SOLUTION | Not given | 5 mg/.5mL | DRUG FOR FURTHER PROCESSING | May 6, 2025 | None given | Dec 31, 2027 |
| 83516-0259 | Resilience US, LLC | Not given | Tirzepatide | INJECTION, SOLUTION | Not given | 7.5 mg/.5mL | DRUG FOR FURTHER PROCESSING | May 6, 2025 | None given | Dec 31, 2027 |
| 83516-0260 | Resilience US, LLC | Not given | Tirzepatide | INJECTION, SOLUTION | Not given | 10 mg/.5mL | DRUG FOR FURTHER PROCESSING | May 6, 2025 | None given | Dec 31, 2027 |
| 83516-0261 | Resilience US, LLC | Not given | Tirzepatide | INJECTION, SOLUTION | Not given | 12.5 mg/.5mL | DRUG FOR FURTHER PROCESSING | Aug 15, 2025 | None given | Dec 31, 2027 |
| 83516-0262 | Resilience US, LLC | Not given | Tirzepatide | INJECTION, SOLUTION | Not given | 15 mg/.5mL | DRUG FOR FURTHER PROCESSING | Aug 15, 2025 | None given | Dec 31, 2027 |
Finished drugs under an NDA, ANDA or BLA
| 50090-2853 NDA022341 | A-S Medication Solutions | Victoza | liraglutide | INJECTION | SUBCUTANEOUS | 6 mg/mL | NDA | Jan 25, 2010 | None given | Dec 31, 2026 |
| 50090-4257 NDA206321 | A-S Medication Solutions | Saxenda | liraglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 6 mg/mL | NDA | Dec 31, 2014 | None given | Dec 31, 2026 |
| 50090-4503 NDA022341 | A-S Medication Solutions | Victoza | liraglutide | INJECTION | SUBCUTANEOUS | 6 mg/mL | NDA | Jan 25, 2010 | None given | Dec 31, 2026 |
| 50090-7501 NDA022341 | A-S Medication Solutions | Liraglutide | liraglutide | INJECTION | SUBCUTANEOUS | 6 mg/mL | NDA AUTHORIZED GENERIC | Jun 24, 2024 | None given | Dec 31, 2026 |
| 50090-8145 ANDA217590 | A-S Medication Solutions | LIRAGLUTIDE | LIRAGLUTIDE | INJECTION, SOLUTION | SUBCUTANEOUS | 6 mg/mL | ANDA | Jan 22, 2026 | None given | Dec 31, 2027 |
| 70377-094 ANDA215245 | Biocon Pharma Inc. | Liraglutide | liraglutide | INJECTION | SUBCUTANEOUS | 6 mg/mL | ANDA | Apr 25, 2026 | None given | Dec 31, 2027 |
| 70377-095 ANDA217063 | Biocon Pharma Inc. | Liraglutide | liraglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 6 mg/mL | ANDA | Mar 27, 2026 | None given | Dec 31, 2027 |
| 69097-910 ANDA217234 | Cipla USA Inc. | liraglutide | liraglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 6 mg/mL | ANDA | Feb 25, 2026 | None given | Dec 31, 2027 |
| 69097-920 ANDA217590 | Cipla USA Inc. | LIRAGLUTIDE | LIRAGLUTIDE | INJECTION, SOLUTION | SUBCUTANEOUS | 6 mg/mL | ANDA | Jan 22, 2026 | None given | Dec 31, 2027 |
| 0143-9144 ANDA215503 | Hikma Pharmaceuticals USA Inc. | Liraglutide | liraglutide | INJECTION | SUBCUTANEOUS | 6 mg/mL | ANDA | Dec 24, 2024 | None given | Dec 31, 2027 |
| 14403-3400 ANDA215503 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Liraglutide | Liraglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 18 mg/3mL | ANDA | Jun 21, 2024 | None given | Dec 31, 2026 |
| 14403-3400 ANDA215503 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Liraglutide | Liraglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 18 mg/3mL | ANDA | Dec 24, 2024 | None given | Dec 31, 2026 |
| 14403-3400 ANDA215503 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Liraglutide | Liraglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 18 mg/3mL | ANDA | Dec 24, 2024 | None given | Dec 31, 2026 |
| 70748-346 ANDA215421 | Lupin Pharmaceuticals, Inc. | Liraglutide | Liraglutide | INJECTION | SUBCUTANEOUS | 6 mg/mL | ANDA | Oct 2, 2025 | None given | Dec 31, 2027 |
| 71288-563 ANDA218115 | Meitheal Pharmaceuticals Inc. | Liraglutide | liraglutide | INJECTION | SUBCUTANEOUS | 6 mg/mL | ANDA | Apr 2, 2025 | None given | Dec 31, 2027 |
| 72603-745 ANDA218115 | NorthStar Rx LLC | Liraglutide | liraglutide | INJECTION | SUBCUTANEOUS | 6 mg/mL | ANDA | Mar 1, 2026 | None given | Dec 31, 2027 |
| 0169-2911 BLA208583 | Novo Nordisk | Xultophy 100/3.6 | insulin degludec and liraglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 100 [iU]/mL; 3.6 mg/mL | BLA | Nov 21, 2016 | None given | Dec 31, 2026 |
| 0169-4060 NDA022341 | Novo Nordisk | Victoza | liraglutide | INJECTION | SUBCUTANEOUS | 6 mg/mL | NDA | Jan 25, 2010 | None given | Dec 31, 2026 |
| 0169-2800 NDA206321 | Novo Nordisk Pharmaceutical Industries, LP | Saxenda | liraglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 6 mg/mL | NDA | Dec 31, 2014 | None given | Dec 31, 2027 |
| 81607-018 ANDA217590 | Orbicular Pharmaceutical Technologies Private Limited | LIRAGLUTIDE | LIRAGLUTIDE | INJECTION, SOLUTION | SUBCUTANEOUS | 6 mg/mL | ANDA | Jan 21, 2026 | None given | Dec 31, 2027 |
| 81607-019 ANDA217234 | Orbicular Pharmaceutical Technologies Private Limited | liraglutide | liraglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 6 mg/mL | ANDA | Feb 26, 2026 | None given | Dec 31, 2027 |
| 0480-3667 NDA022341 | Teva Pharmaceuticals USA, Inc. | Liraglutide | liraglutide | INJECTION | SUBCUTANEOUS | 6 mg/mL | NDA AUTHORIZED GENERIC | Jun 24, 2024 | None given | Dec 31, 2027 |
| 0480-7250 ANDA214568 | Teva Pharmaceuticals, Inc. | Liraglutide | Liraglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 6 mg/mL | ANDA | Aug 28, 2025 | Sep 30, 2027 | Not given |
| 50090-5824 NDA215256 | A-S Medication Solutions | WEGOVY | semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | .25 mg/.5mL | NDA | Jun 5, 2021 | None given | Dec 31, 2026 |
| 50090-5949 NDA209637 | A-S Medication Solutions | Ozempic | semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 1.34 mg/mL | NDA | Sep 30, 2020 | None given | Dec 31, 2026 |
| 50090-6051 NDA209637 | A-S Medication Solutions | OZEMPIC | semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 2.68 mg/mL | NDA | Apr 25, 2022 | None given | Dec 31, 2026 |
| 50090-8027 NDA209637 | A-S Medication Solutions | Ozempic | semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | .68 mg/mL | NDA | Oct 7, 2022 | None given | Dec 31, 2027 |
| 0169-1704 NDA213051 | Novo Nordisk Pharmaceutical Industries, LP | OZEMPIC | oral semaglutide | TABLET | ORAL | 4 mg/1 | NDA | Apr 27, 2026 | None given | Dec 31, 2027 |
| 0169-1709 NDA213051 | Novo Nordisk Pharmaceutical Industries, LP | OZEMPIC | oral semaglutide | TABLET | ORAL | 9 mg/1 | NDA | Apr 27, 2026 | None given | Dec 31, 2027 |
| 0169-1715 NDA213051 | Novo Nordisk Pharmaceutical Industries, LP | OZEMPIC | oral semaglutide | TABLET | ORAL | 1.5 mg/1 | NDA | Apr 27, 2026 | None given | Dec 31, 2027 |
| 0169-4130 NDA209637 | Novo Nordisk Pharmaceutical Industries, LP | Ozempic | semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 1.34 mg/mL | NDA | Sep 30, 2020 | None given | Dec 31, 2027 |
| 0169-4181 NDA209637 | Novo Nordisk Pharmaceutical Industries, LP | Ozempic | semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | .68 mg/mL | NDA | Oct 7, 2022 | None given | Dec 31, 2027 |
| 0169-4303 NDA213051 | Novo Nordisk Pharmaceutical Industries, LP | RYBELSUS | oral semaglutide | TABLET | ORAL | 3 mg/1 | NDA | Sep 20, 2019 | None given | Dec 31, 2027 |
| 0169-4307 NDA213051 | Novo Nordisk Pharmaceutical Industries, LP | RYBELSUS | oral semaglutide | TABLET | ORAL | 7 mg/1 | NDA | Sep 20, 2019 | None given | Dec 31, 2027 |
| 0169-4314 NDA213051 | Novo Nordisk Pharmaceutical Industries, LP | RYBELSUS | oral semaglutide | TABLET | ORAL | 14 mg/1 | NDA | Sep 20, 2019 | None given | Dec 31, 2027 |
| 0169-4404 NDA218316 | Novo Nordisk Pharmaceutical Industries, LP | WEGOVY | semaglutide | TABLET | ORAL | 4 mg/1 | NDA | Jan 6, 2026 | None given | Dec 31, 2027 |
| 0169-4409 NDA218316 | Novo Nordisk Pharmaceutical Industries, LP | WEGOVY | semaglutide | TABLET | ORAL | 9 mg/1 | NDA | Jan 6, 2026 | None given | Dec 31, 2027 |
| 0169-4415 NDA218316 | Novo Nordisk Pharmaceutical Industries, LP | WEGOVY | semaglutide | TABLET | ORAL | 1.5 mg/1 | NDA | Jan 6, 2026 | None given | Dec 31, 2027 |
| 0169-4425 NDA218316 | Novo Nordisk Pharmaceutical Industries, LP | WEGOVY | semaglutide | TABLET | ORAL | 25 mg/1 | NDA | Jan 6, 2026 | None given | Dec 31, 2027 |
| 0169-4501 NDA215256 | Novo Nordisk Pharmaceutical Industries, LP | WEGOVY | semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 1 mg/.5mL | NDA | Jun 5, 2021 | None given | Dec 31, 2027 |
| 0169-4505 NDA215256 | Novo Nordisk Pharmaceutical Industries, LP | WEGOVY | semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | .5 mg/.5mL | NDA | Jun 5, 2021 | None given | Dec 31, 2027 |
| 0169-4517 NDA215256 | Novo Nordisk Pharmaceutical Industries, LP | WEGOVY | semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 1.7 mg/.75mL | NDA | Jun 5, 2021 | None given | Dec 31, 2027 |
| 0169-4524 NDA215256 | Novo Nordisk Pharmaceutical Industries, LP | WEGOVY | semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 2.4 mg/.75mL | NDA | Jun 5, 2021 | None given | Dec 31, 2027 |
| 0169-4525 NDA215256 | Novo Nordisk Pharmaceutical Industries, LP | WEGOVY | semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | .25 mg/.5mL | NDA | Jun 5, 2021 | None given | Dec 31, 2027 |
| 0169-4572 NDA215256 | Novo Nordisk Pharmaceutical Industries, LP | WEGOVY | semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 7.2 mg/.75mL | NDA | Jun 5, 2021 | None given | Dec 31, 2027 |
| 0169-4772 NDA209637 | Novo Nordisk Pharmaceutical Industries, LP | Ozempic | semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 2.68 mg/mL | NDA | Apr 25, 2022 | None given | Dec 31, 2027 |
| 0169-4915 NDA215256 | Novo Nordisk Pharmaceutical Industries, LP | WEGOVY | semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 3.2 mg/mL | NDA | Jun 5, 2021 | None given | Dec 31, 2027 |
| 50090-8021 NDA215866 | A-S Medication Solutions | MOUNJARO | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 10 mg/.5mL | NDA | May 13, 2022 | None given | Dec 31, 2027 |
| 50090-8022 NDA215866 | A-S Medication Solutions | MOUNJARO | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 12.5 mg/.5mL | NDA | May 13, 2022 | None given | Dec 31, 2027 |
| 50090-8023 NDA215866 | A-S Medication Solutions | MOUNJARO | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 7.5 mg/.5mL | NDA | May 13, 2022 | None given | Dec 31, 2027 |
| 50090-8024 NDA215866 | A-S Medication Solutions | MOUNJARO | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 5 mg/.5mL | NDA | May 13, 2022 | None given | Dec 31, 2027 |
| 50090-8025 NDA215866 | A-S Medication Solutions | MOUNJARO | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/.5mL | NDA | May 13, 2022 | None given | Dec 31, 2027 |
| 50090-8026 NDA215866 | A-S Medication Solutions | MOUNJARO | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 15 mg/.5mL | NDA | May 13, 2022 | None given | Dec 31, 2027 |
| 0002-0152 NDA217806 | Eli Lilly and Company | Zepbound | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/.5mL | NDA | Mar 28, 2024 | None given | Dec 31, 2027 |
| 0002-0243 NDA217806 | Eli Lilly and Company | Zepbound | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 5 mg/.5mL | NDA | Mar 28, 2024 | None given | Dec 31, 2027 |
| 0002-1152 NDA215866 | Eli Lilly and Company | Mounjaro | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/.5mL | NDA | Jul 28, 2023 | None given | Dec 31, 2027 |
| 0002-1214 NDA217806 | Eli Lilly and Company | Zepbound | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 7.5 mg/.5mL | NDA | Mar 28, 2024 | None given | Dec 31, 2027 |
| 0002-1243 NDA215866 | Eli Lilly and Company | Mounjaro | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 5 mg/.5mL | NDA | Jul 28, 2023 | None given | Dec 31, 2027 |
| 0002-1340 NDA217806 | Eli Lilly and Company | Zepbound | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 10 mg/.5mL | NDA | Mar 28, 2024 | None given | Dec 31, 2027 |
| 0002-1423 NDA217806 | Eli Lilly and Company | Zepbound | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 12.5 mg/.5mL | NDA | Mar 28, 2024 | None given | Dec 31, 2027 |
| 0002-1457 NDA215866 | Eli Lilly and Company | Mounjaro | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 15 mg/.5mL | NDA | May 13, 2022 | None given | Dec 31, 2027 |
| 0002-1460 NDA215866 | Eli Lilly and Company | Mounjaro | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 12.5 mg/.5mL | NDA | May 13, 2022 | None given | Dec 31, 2027 |
| 0002-1471 NDA215866 | Eli Lilly and Company | Mounjaro | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 10 mg/.5mL | NDA | May 13, 2022 | None given | Dec 31, 2027 |
| 0002-1484 NDA215866 | Eli Lilly and Company | Mounjaro | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 7.5 mg/.5mL | NDA | May 13, 2022 | None given | Dec 31, 2027 |
| 0002-1495 NDA215866 | Eli Lilly and Company | Mounjaro | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 5 mg/.5mL | NDA | May 13, 2022 | None given | Dec 31, 2027 |
| 0002-1506 NDA215866 | Eli Lilly and Company | Mounjaro | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/.5mL | NDA | May 13, 2022 | None given | Dec 31, 2027 |
| 0002-2002 NDA217806 | Eli Lilly and Company | Zepbound | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 15 mg/.5mL | NDA | Mar 28, 2024 | None given | Dec 31, 2027 |
| 0002-2214 NDA215866 | Eli Lilly and Company | Mounjaro | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 7.5 mg/.5mL | NDA | Jul 28, 2023 | None given | Dec 31, 2027 |
| 0002-2340 NDA215866 | Eli Lilly and Company | Mounjaro | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 10 mg/.5mL | NDA | Jul 28, 2023 | None given | Dec 31, 2027 |
| 0002-2423 NDA215866 | Eli Lilly and Company | Mounjaro | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 12.5 mg/.5mL | NDA | Jul 28, 2023 | None given | Dec 31, 2027 |
| 0002-2457 NDA217806 | Eli Lilly and Company | ZEPBOUND | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 15 mg/.5mL | NDA | Nov 8, 2023 | None given | Dec 31, 2027 |
| 0002-2460 NDA217806 | Eli Lilly and Company | ZEPBOUND | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 12.5 mg/.5mL | NDA | Nov 8, 2023 | None given | Dec 31, 2027 |
| 0002-2471 NDA217806 | Eli Lilly and Company | ZEPBOUND | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 10 mg/.5mL | NDA | Nov 8, 2023 | None given | Dec 31, 2027 |
| 0002-2484 NDA217806 | Eli Lilly and Company | ZEPBOUND | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 7.5 mg/.5mL | NDA | Nov 8, 2023 | None given | Dec 31, 2027 |
| 0002-2495 NDA217806 | Eli Lilly and Company | ZEPBOUND | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 5 mg/.5mL | NDA | Nov 8, 2023 | None given | Dec 31, 2027 |
| 0002-2506 NDA217806 | Eli Lilly and Company | ZEPBOUND | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/.5mL | NDA | Nov 8, 2023 | None given | Dec 31, 2027 |
| 0002-3002 NDA215866 | Eli Lilly and Company | Mounjaro | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 15 mg/.5mL | NDA | Jul 28, 2023 | None given | Dec 31, 2027 |
| 0002-3411 NDA215866 | Eli Lilly and Company | Mounjaro KwikPen | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 25 mg/mL | NDA | Jan 20, 2026 | None given | Dec 31, 2027 |
| 0002-3422 NDA215866 | Eli Lilly and Company | Mounjaro KwikPen | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 20.8 mg/mL | NDA | Jan 20, 2026 | None given | Dec 31, 2027 |
| 0002-3433 NDA215866 | Eli Lilly and Company | Mounjaro KwikPen | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 16.7 mg/mL | NDA | Jan 20, 2026 | None given | Dec 31, 2027 |
| 0002-3444 NDA215866 | Eli Lilly and Company | Mounjaro KwikPen | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 12.5 mg/mL | NDA | Jan 20, 2026 | None given | Dec 31, 2027 |
| 0002-3455 NDA215866 | Eli Lilly and Company | Mounjaro KwikPen | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 8.33 mg/mL | NDA | Jan 20, 2026 | None given | Dec 31, 2027 |
| 0002-3466 NDA215866 | Eli Lilly and Company | Mounjaro KwikPen | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 4.17 mg/mL | NDA | Jan 20, 2026 | None given | Dec 31, 2027 |
| 0002-3511 NDA217806 | Eli Lilly and Company | Zepbound KwikPen | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 25 mg/mL | NDA | Jan 20, 2026 | None given | Dec 31, 2027 |
| 0002-3522 NDA217806 | Eli Lilly and Company | Zepbound KwikPen | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 20.8 mg/mL | NDA | Jan 20, 2026 | None given | Dec 31, 2027 |
| 0002-3533 NDA217806 | Eli Lilly and Company | Zepbound KwikPen | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 16.7 mg/mL | NDA | Jan 20, 2026 | None given | Dec 31, 2027 |
| 0002-3544 NDA217806 | Eli Lilly and Company | Zepbound KwikPen | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 12.5 mg/mL | NDA | Jan 20, 2026 | None given | Dec 31, 2027 |
| 0002-3555 NDA217806 | Eli Lilly and Company | Zepbound KwikPen | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 8.33 mg/mL | NDA | Jan 20, 2026 | None given | Dec 31, 2027 |
| 0002-3566 NDA217806 | Eli Lilly and Company | Zepbound KwikPen | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 4.17 mg/mL | NDA | Jan 20, 2026 | None given | Dec 31, 2027 |
| 0002-4052 NDA215866 | Eli Lilly and Company | Mounjaro | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 4.17 mg/mL | NDA | Jan 7, 2026 | None given | Dec 31, 2027 |
| 0002-4103 NDA215866 | Eli Lilly and Company | Mounjaro | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 8.33 mg/mL | NDA | Jan 7, 2026 | None given | Dec 31, 2027 |
| 0002-4210 NDA215866 | Eli Lilly and Company | Mounjaro | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 12.5 mg/mL | NDA | Jan 7, 2026 | None given | Dec 31, 2027 |
| 0002-4304 NDA215866 | Eli Lilly and Company | Mounjaro | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 16.7 mg/mL | NDA | Jan 7, 2026 | None given | Dec 31, 2027 |
| 0002-4523 NDA215866 | Eli Lilly and Company | Mounjaro | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 20.8 mg/mL | NDA | Jan 7, 2026 | None given | Dec 31, 2027 |
| 0002-4612 NDA215866 | Eli Lilly and Company | Mounjaro | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 25 mg/mL | NDA | Jan 7, 2026 | None given | Dec 31, 2027 |
| 0002-6052 NDA217806 | Eli Lilly and Company | Zepbound | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 4.17 mg/mL | NDA | Jan 7, 2026 | None given | Dec 31, 2027 |
| 0002-6103 NDA217806 | Eli Lilly and Company | Zepbound | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 8.33 mg/mL | NDA | Jan 7, 2026 | None given | Dec 31, 2027 |
| 0002-6210 NDA217806 | Eli Lilly and Company | Zepbound | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 12.5 mg/mL | NDA | Jan 7, 2026 | None given | Dec 31, 2027 |
| 0002-6304 NDA217806 | Eli Lilly and Company | Zepbound | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 16.7 mg/mL | NDA | Jan 7, 2026 | None given | Dec 31, 2027 |
| 0002-6523 NDA217806 | Eli Lilly and Company | Zepbound | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 20.8 mg/mL | NDA | Jan 7, 2026 | None given | Dec 31, 2027 |
| 0002-6612 NDA217806 | Eli Lilly and Company | Zepbound | tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 25 mg/mL | NDA | Jan 7, 2026 | None given | Dec 31, 2027 |
Listings FDA removed or excluded from the Directory
FDA’s excluded drugs file leaves the substance name blank on most rows, so its rows were matched by a tracked drug in any name field or by an application number that a tracked-drug listing in the finished or unfinished files carries; a row with blank names and no application number cannot be matched. 8 rows matched, all under NDA. No compounded, bulk or other non-application listing naming a tracked drug was found in the excluded file read Nov 15, 2026; that is a statement about this one FDA file, nothing more.
| 50090-5138 NDA209637 | A-S Medication Solutions | Ozempic | Not given | Not given | Not given | Not given | NDA Flag I: Inactivated by the FDA. | Dec 6, 2017 | None given | Dec 31, 2022 |
| 50090-5139 NDA209637 | A-S Medication Solutions | Ozempic | Not given | Not given | Not given | Not given | NDA Flag I: Inactivated by the FDA. | Dec 6, 2017 | None given | Dec 31, 2022 |
| 0169-4132 NDA209637 | Novo Nordisk Pharmaceutical Industries, LP | Ozempic | Not given | Not given | Not given | Not given | NDA Flag D: Discontinued by the firm. | Dec 6, 2017 | Sep 30, 2025 | Sep 30, 2025 |
| 0169-4136 NDA209637 | Novo Nordisk Pharmaceutical Industries, LP | Ozempic | Not given | Not given | Not given | Not given | NDA Flag D: Discontinued by the firm. | Dec 6, 2017 | Oct 31, 2023 | Oct 31, 2023 |
| 0169-4804 NDA213051 | Novo Nordisk Pharmaceutical Industries, LP | RYBELSUS | Not given | Not given | Not given | Not given | NDA Flag D: Discontinued by the firm. | Sep 20, 2019 | Mar 31, 2025 | Mar 31, 2025 |
| 0169-4809 NDA213051 | Novo Nordisk Pharmaceutical Industries, LP | RYBELSUS | Not given | Not given | Not given | Not given | NDA Flag D: Discontinued by the firm. | Sep 20, 2019 | Mar 31, 2025 | Mar 31, 2025 |
| 0169-4815 NDA213051 | Novo Nordisk Pharmaceutical Industries, LP | RYBELSUS | Not given | Not given | Not given | Not given | NDA Flag D: Discontinued by the firm. | Sep 20, 2019 | Mar 31, 2025 | Mar 31, 2025 |
| 70518-2143 NDA209637 | REMEDYREPACK INC. | Ozempic | Not given | Not given | Not given | Not given | NDA Flag D: Discontinued by the firm. | Jun 11, 2019 | May 3, 2021 | May 3, 2021 |
Files read
| FDA file | File date | Rows in file | GLP-1 listings kept |
|---|---|---|---|
| NDC database file (finished drugs) (product.txt) | Nov 10, 2026 | 116659 | 101 |
| NDC unfinished drugs database file (unfinished_product.txt) | Nov 10, 2026 | 21666 | 283 |
| NDC compounded drugs database file (compounders_ndc_directory.txt) | Sep 18, 2026 | 4836 | 75 |
| NDC database excluded drugs database file (Products_excluded.txt) | Nov 10, 2026 | 207511 | 8 |
The compounded file groups package rows into one listing per product NDC. As a cross-check, openFDA’s drug NDC endpoint reported 142 for semaglutide, 168 for tirzepatide, 62 for liraglutide, 11 for retatrutide, 1 for cagrilintide (finished and unfinished listings) on Nov 15, 2026. The compounded drugs file holds the product reports of outsourcing facilities that elected to assign NDCs, so a facility that compounds a drug without reporting an NDC for it does not appear there.
Sources
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.